Circulation and degradation of GIP and GLP-1

被引:221
|
作者
Deacon, CF [1 ]
机构
[1] Panum Inst, Dept Med Physiol, DK-2200 Copenhagen N, Denmark
关键词
glucagon-like peptide-1; glucose-dependent insulinotropic polypeptide; gut hormone; incretin; dipeptidyl peptidase IV; neutral endopeptidase 24.11;
D O I
10.1055/s-2004-826160
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted from the intestinal K- and L-cells, respectively, but are immediately subject to rapid degradation. GLP-1 is found in two active forms, amidated GLP-1 (7-36) amide and glycine-extended GLP-1 (7-37), while GIP exists as a single 42 amino acid peptide. The aminopeptidase, dipeptidyl peptidase IV (DPP IV), which is found in the endothelium of the local capillary bed within the intestinal wall, is important for the initial inactivation of both peptides, with GLP-1 being particularly readily degraded. DPP IV cleavage generates N-terminally truncated metabolites (GLP-1 (9-36) amide / (9-37) and GIP (3-42)), which are the major circulating forms. Subsequently, the peptides may be degraded by other enzymes and extracted in an organ-specific manner. However, other endogenous metabolites have not yet been identified, possibly because existing assays are unable either to recognize them or to differentiate them from the primary metabolites. Neutral endopeptidase 24.11 has been demonstrated to be able to degrade GLP-1 in vivo, but its relevance in GIP metabolism has not yet been established. Intact GLP-1 and GIP are inactivated during passage across the hepatic bed by DPP IV associated with the hepatocytes, and further degraded by the peripheral tissues, while the kidney is important for the final elimination of the metabolites.
引用
收藏
页码:761 / 765
页数:5
相关论文
共 50 条
  • [41] GLP-1 and GIP contribute nearly equally to the incretin effect in humans
    Vilsboll, T
    Krarup, T
    Madsbad, S
    Holst, J
    DIABETES, 2003, 52 : A325 - A325
  • [42] GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine
    Mortensen, K
    Christensen, LL
    Holst, JJ
    Orskov, C
    REGULATORY PEPTIDES, 2003, 114 (2-3) : 189 - 196
  • [43] CART regulates GIP and GLP-1 expression and secretion in vitro and in vivo
    Shcherbina, L.
    Fischer, A. -H. Thoren
    Wierup, N.
    DIABETOLOGIA, 2015, 58 : S272 - S273
  • [44] GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy
    Lafferty, Ryan. A. A.
    Flatt, Peter. R. R.
    Irwin, Nigel
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (05) : 587 - 597
  • [45] Neural mechanisms contribute to islet effects of both GLP-1 and GIP
    Ahlkvist, L.
    Ahren, B.
    DIABETOLOGIA, 2014, 57 : S223 - S223
  • [46] GLP-1 and GIP Levels in Patients With Hyperthyroidism: The Effect of Antithyroid Treatment
    Cira, Duygu Kalkan
    Sari, Ramazan
    Ozdem, Sebahat
    Yilmaz, Nusret
    Bozkurt, Selen
    ANNALS OF PHARMACOTHERAPY, 2017, 51 (08) : 663 - 668
  • [47] Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes
    Gautier, J. -F.
    Choukem, S. -P.
    Girard, J.
    DIABETES & METABOLISM, 2008, 34 : S65 - S72
  • [48] Redundant Effect of GIP and GLP-1 on Insulin Secretion in Normal Mice
    Pacini, Giovanni
    Ahren, Bo
    DIABETES, 2015, 64 : A498 - A498
  • [49] GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals
    Gasbjerg, Laerke S.
    Helsted, Mads M.
    Hartmann, Bolette
    Sparre-Ulrich, Alexander H.
    Veedfald, Simon
    Stensen, Signe
    Lanng, Amalie R.
    Bergmann, Natasha C.
    Christensen, Mikkel B.
    Vilsboll, Tina
    Holst, Jens J.
    Rosenkilde, Mette M.
    Knop, Filip K.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (03): : E725 - E738
  • [50] Spatiotemporal Dynamics of GLP-1 Receptor and GIP Receptor Trafficking and Signaling in β Cells
    Ayala, Julio E.
    ENDOCRINOLOGY, 2023, 164 (06)